Trial Details
WITHDRAWNBasic Information
| Clinical ID | c1855 |
|---|---|
| Identifier | NCT03035058 |
| Trial Title | Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Primary Sclerosing Cholangitis; Inflammatory Bowel Disease |
| Interventions | DRUG: Vedolizumab; DRUG: Placebo |
Participant Information
| Sponsor | Takeda |
|---|---|
| City | - |
| Country/Region | - |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | - |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2025-02-17 |
|---|---|
| Primary Completion Date | 2025-09-20 |
| Completion Date | 2025-01-21 |